The estimated Net Worth of Capital (Master), L.P.Sessa... is at least $470 Milion dollars as of 14 April 2023. Capital Sessa owns over 2,190,549 units of Provention Bio stock worth over $388,876,075 and over the last 2 years Capital sold PRVB stock worth over $81,474,152.
Capital has made over 2 trades of the Provention Bio stock since 2023, according to the Form 4 filled with the SEC. Most recently Capital sold 2,190,549 units of PRVB stock worth $53,274,152 on 14 April 2023.
The largest trade Capital's ever made was selling 3,000,000 units of Provention Bio stock on 18 January 2023 worth over $28,200,000. On average, Capital trades about 1,038,110 units every 17 days since 2023. As of 14 April 2023 Capital still owns at least 15,567,497 units of Provention Bio stock.
You can see the complete history of Capital Sessa stock trades at the bottom of the page.
Over the last 6 years, insiders at Provention Bio have traded over $81,606,241 worth of Provention Bio stock and bought 165,475 units worth $1,543,065 . The most active insiders traders include Capital (Master), L.P.Sessa..., Nancy Wysenski oraz Avery W Catlin. On average, Provention Bio executives and independent directors trade stock every 35 days with the average trade being worth of $3,621,900. The most recent stock trade was executed by Capital (Master), L.P.Sessa... on 14 April 2023, trading 2,190,549 units of PRVB stock currently worth $53,274,152.
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Provention Bio executives and other stock owners filed with the SEC include: